Trial Profile
An open label, repeat dose, dose escalation study conducted in RLS [restless legs syndrome] patients to characterize pharmacokinetics and food effect of ropinirole controlled release for RLS.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2008 Actual start date changed from Sep 2006 to Aug 2006 as reported by Clinicaltrials.gov
- 12 Oct 2008 Trial phase changed from II to I as reported by ClinicalTrials.gov.
- 04 Sep 2007 Status changed from recruiting to completed.